Google
KRYS — KRYSTAL BIOTECH INC (Healthcare >> Biotechnology)
KRYS FAQ
What is KRYS's P/E ratio?
KRYSTAL BIOTECH INC (KRYS) currently trades at a P/E ratio of 39.43.
What is KRYS's ROE?
KRYSTAL BIOTECH INC reports a Return on Equity (ROE) of 17.63%.
What is KRYS's dividend yield?
KRYSTAL BIOTECH INC offers a dividend yield of 0.00%.
What is KRYS's Deepscope Quality Score?
Deepscope rates KRYS's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KRYS?
Deepscope's AI Timing Score for KRYS is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KRYS belong to?
KRYSTAL BIOTECH INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 301.00
Price
-6.79
(-2.21%)
Day Change
|
|
|---|
KRYS, the overall quality is very good ( Quality = 85) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Historical ROE is relatively low
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.55 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1255
|
| Magic Formula Rank by ROE |
1255
|
| Magic Formula Rank by ROIC |
1227
|
| Price | 301.00 |
| PBV / Sector |
6.95 / 4.63
|
| Earning Per Share | 7.63 |
| PE / Sector |
39.43 / 17.43
|
| PEG or PE/Growth / Sector |
0.17 / 0.53
GREAT
|
| Average 1M Daily Value |
78.43 M
|
| Average 1W Daily Value |
80.85 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KRYS |
| Name | KRYSTAL BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,873.41 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
Phone: 412 586 5830
Website: https://www.krystalbio.com
Employees: 295
Sector: Healthcare >> Biotechnology
Description: Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
